These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14623006)

  • 21. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
    Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
    Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
    Clements JM; Beckett RP; Brown A; Catlin G; Lobell M; Palan S; Thomas W; Whittaker M; Wood S; Salama S; Baker PJ; Rodgers HF; Barynin V; Rice DW; Hunter MG
    Antimicrob Agents Chemother; 2001 Feb; 45(2):563-70. PubMed ID: 11158755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of a macrocyclic inhibitor for peptide deformylase.
    Hu X; Nguyen KT; Verlinde CL; Hol WG; Pei D
    J Med Chem; 2003 Aug; 46(18):3771-4. PubMed ID: 12930137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis, and Biological Evaluation of Vanillin Hydroxamic Acid Derivatives as Novel Peptide Deformylase Inhibitors.
    Gao J; Qiu S; Liang L; Hao Z; Zhou Q; Wang F; Mou J; Lin Q
    Curr Comput Aided Drug Des; 2018; 14(1):95-101. PubMed ID: 28606047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
    Montgomery JI; Brown MF; Reilly U; Price LM; Abramite JA; Arcari J; Barham R; Che Y; Chen JM; Chung SW; Collantes EM; Desbonnet C; Doroski M; Doty J; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; McAllister L; McElroy E; Menard CA; Mitton-Fry M; Mullins L; Noe MC; O'Donnell J; Oliver R; Penzien J; Plummer M; Shanmugasundaram V; Thoma C; Tomaras AP; Uccello DP; Vaz A; Wishka DG
    J Med Chem; 2012 Feb; 55(4):1662-70. PubMed ID: 22257165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxamic acids as potent inhibitors of Fe(II) and Mn(II) E. coli methionine aminopeptidase: biological activities and X-ray structures of oxazole hydroxamate-EcMetAP-Mn complexes.
    Huguet F; Melet A; Alves de Sousa R; Lieutaud A; Chevalier J; Maigre L; Deschamps P; Tomas A; Leulliot N; Pages JM; Artaud I
    ChemMedChem; 2012 Jun; 7(6):1020-30. PubMed ID: 22489069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
    Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
    Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship analysis of the peptide deformylase inhibitor 5-bromo-1H-indole-3-acetohydroxamic acid.
    Petit S; Duroc Y; Larue V; Giglione C; Léon C; Soulama C; Denis A; Dardel F; Meinnel T; Artaud I
    ChemMedChem; 2009 Feb; 4(2):261-75. PubMed ID: 19053131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
    Panchaud P; Surivet JP; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Enderlin-Paput M; Lange R; Gnerre C; Seeland S; Herrmann C; Locher HH; Seiler P; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):88-102. PubMed ID: 31804829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibitors of LpxC for the treatment of Gram-negative infections.
    Brown MF; Reilly U; Abramite JA; Arcari JT; Oliver R; Barham RA; Che Y; Chen JM; Collantes EM; Chung SW; Desbonnet C; Doty J; Doroski M; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; Marra A; McElroy E; Melnick M; Menard CA; Montgomery JI; Mullins L; Noe MC; O'Donnell J; Penzien J; Plummer MS; Price LM; Shanmugasundaram V; Thoma C; Uccello DP; Warmus JS; Wishka DG
    J Med Chem; 2012 Jan; 55(2):914-23. PubMed ID: 22175825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and antibacterial activity of peptide deformylase inhibitors.
    Huntington KM; Yi T; Wei Y; Pei D
    Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and refinement of a new structural class of potent peptide deformylase inhibitors.
    Boularot A; Giglione C; Petit S; Duroc Y; Alves de Sousa R; Larue V; Cresteil T; Dardel F; Artaud I; Meinnel T
    J Med Chem; 2007 Jan; 50(1):10-20. PubMed ID: 17201406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial N-(2-chlorobenzyl)-substituted hydroxamate is an inhibitor of 1-deoxy-D-xylulose 5-phosphate synthase.
    Hayashi D; Kato N; Kuzuyama T; Sato Y; Ohkanda J
    Chem Commun (Camb); 2013 Jun; 49(49):5535-7. PubMed ID: 23476925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
    Apfel C; Banner DW; Bur D; Dietz M; Hubschwerlen C; Locher H; Marlin F; Masciadri R; Pirson W; Stalder H
    J Med Chem; 2001 Jun; 44(12):1847-52. PubMed ID: 11384231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents.
    Jain R; Chen D; White RJ; Patel DV; Yuan Z
    Curr Med Chem; 2005; 12(14):1607-21. PubMed ID: 16022661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and characterisation of Co(iii) complexes of N-formyl hydroxylamines and antibacterial activity of a Co(iii) peptide deformylase inhibitor complex.
    Kozsup M; Keogan DM; Fitzgerald-Hughes D; Enyedy ÉA; Twamley B; Buglyó P; Griffith DM
    Dalton Trans; 2020 Jun; 49(21):6980-6988. PubMed ID: 32347254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial Peptide Deformylase Inhibition of Tetrazole-Substituted Biaryl Acid Analogs: Synthesis, Biological Evaluations, and Molecular Docking Study.
    Khan FA; Patil RH; Patil M; Arote R; Shinde DB; Sangshetti JN
    Arch Pharm (Weinheim); 2016 Dec; 349(12):934-943. PubMed ID: 27859538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.